Departamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de México, México.
Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Ciudad de México, México.
Arch Med Res. 2018 Jan;49(1):18-26. doi: 10.1016/j.arcmed.2018.04.010. Epub 2018 Apr 24.
The variation in cystic fibrosis (CF) lung disease not always is explained by the CFTR genotype, so it has become apparent that modifier genes must play a considerable role in the phenotypic heterogeneity of CF, so we investigated the association of allelic variants in modifier genes that modulate the severity of lung function in a group of Mexican patients diagnosed with CF.
We included 140 CF patients classified according to lung phenotype and analyzed 17 single nucleotide polymorphisms (SNPs) by TaqMan allelic discrimination.
We demonstrated that patients with GG or GC genotype of the allelic variant rs11003125 (MBL2-550) of the MBL2 gene exhibit most of the lung manifestations at an earlier age; and the rs1042713 allelic variant of ADRB2 gene, showed statistical difference only with the age of first spirometry. When we used the dominant model, the MBL2 allele rs11003125 (MBL2-550; p = 0.022, Odds Ratio (OR) 2.87, 95% CI 1.14-7.27) was significantly associated with CF patients as risk factor, and the ADRB2 allele rs1042713 (p.Arg16Gly; p = 0.005, Odds Ratio (OR) 0.37, 95% CI 0.19-0.75) was significantly associated with CF patients as protect factor.
Our findings suggest that the MBL2 and ADRB2 genes exerts an important genetic influence on the lung disease in our patients. Taking into account our results, we insist on not leaving aside this type of studies, since having techniques such as GWAS or WES will be able to advance in achieving a better quality of life for CF patients with severe lung disease.
囊性纤维化 (CF) 肺病的变异并不能总是用 CFTR 基因型来解释,因此很明显,修饰基因在 CF 的表型异质性中必须发挥相当大的作用,所以我们研究了调节基因的等位基因变体与一组墨西哥 CF 患者的肺功能严重程度的相关性。
我们纳入了 140 名根据肺表型分类的 CF 患者,并通过 TaqMan 等位基因鉴别分析了 17 个单核苷酸多态性 (SNP)。
我们证明了 MBL2 基因的等位基因变体 rs11003125 (MBL2-550) GG 或 GC 基因型的患者更早出现大多数肺部表现;ADRB2 基因的 rs1042713 等位基因变体仅与首次肺功能检查的年龄存在统计学差异。当我们使用显性模型时,MBL2 等位基因 rs11003125 (MBL2-550; p = 0.022, 优势比 (OR) 2.87, 95%置信区间 1.14-7.27) 与 CF 患者作为风险因素显著相关,ADRB2 等位基因 rs1042713 (p.Arg16Gly; p = 0.005, 优势比 (OR) 0.37, 95%置信区间 0.19-0.75) 与 CF 患者作为保护因素显著相关。
我们的研究结果表明,MBL2 和 ADRB2 基因对我们患者的肺部疾病有重要的遗传影响。考虑到我们的结果,我们坚持不忽视这种类型的研究,因为拥有 GWAS 或 WES 等技术将能够为患有严重肺部疾病的 CF 患者提高生活质量。